Concepedia
Statistics
Publications
12
Citations
737
H-Index
11
Active since
1995
Affiliations
GlaxoSmithKline (United States)(Current)
Research Triangle Park Foundation
Eli Lilly (United States)
Todd M. Baughman is an author at GlaxoSmithKline (United States) specializing in pharmacology, medicine, and pharmacokinetics.
Publications per year
1995–2018
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Anne H. Dantzig, Robert L. Shepard, Jin Cao et al. · PubMed · 1996 · 328 citations
Medicine, Oncology, Pharmacology +17
Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein
James J. Starling, Robert L. Shepard, Jin Cao et al. · Advances in Enzyme Regulation · 1997 · 86 citations
Medicine, Medicinal Chemistry, Pharmacology +5
P‐glycoprotein Influences the Brain Concentrations of Cetirizine (Zyrtec®), a Second‐Generation Non‐Sedating Antihistamine
Joseph W. Polli, Todd M. Baughman, Joan E. Humphreys et al. · Journal of Pharmaceutical Sciences · 2003 · 86 citations
Medicine, Pharmacokinetics, Pharmacology +8
METABOLIC ACTIVATION OF PIOGLITAZONE IDENTIFIED FROM RAT AND HUMAN LIVER MICROSOMES AND FRESHLY ISOLATED HEPATOCYTES
Todd M. Baughman, Rachel Graham, Kevin J. Wells‐Knecht et al. · Drug Metabolism and Disposition · 2005 · 41 citations
Medicine, Medicinal Chemistry, Pharmacology +8
Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
William J. Ehlhardt, Joseph M. Woodland, Todd M. Baughman et al. · PubMed · 1998 · 40 citations
Medicine, Pharmacokinetics, Pharmacology +15
1–5 of 12